VTv Therapeutics Valuation
| VTVT Stock | USD 15.51 0.09 0.58% |
At this time, the company appears to be overvalued. vTv Therapeutics has a current Real Value of $7.95 per share. The regular price of the company is $15.51. Our model measures the value of vTv Therapeutics from inspecting the company fundamentals such as Current Valuation of (1.08 M), shares owned by insiders of 38.82 %, and Return On Equity of -3.62 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting VTv Therapeutics' valuation include:
Price Book 2.684 | Enterprise Value -1.1 M | Enterprise Value Ebitda (2.11) | Price Sales 40.281 | Enterprise Value Revenue 5.3125 |
Overvalued
Today
Please note that VTv Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of vTv Therapeutics is based on 3 months time horizon. Increasing VTv Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
VTv Therapeutics' intrinsic value may or may not be the same as its current market price of 15.51, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.51 | Real 7.95 | Target 3.0 | Hype 15.57 | Naive 15.54 |
The intrinsic value of VTv Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence VTv Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of vTv Therapeutics helps investors to forecast how VTv stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VTv Therapeutics more accurately as focusing exclusively on VTv Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use VTv Therapeutics' intrinsic value based on its ongoing forecasts of VTv Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against VTv Therapeutics' closest peers.
VTv Therapeutics Cash |
|
VTv Valuation Trend
VTv Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of VTv Therapeutics' financial worth over time. Using both VTv Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
VTv Therapeutics Total Value Analysis
vTv Therapeutics is at this time anticipated to have valuation of (1.08 M) with market capitalization of 40.28 M, debt of 529 K, and cash on hands of 17.95 M. The negative valuation of VTv Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the VTv Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(1.08 M) | 40.28 M | 529 K | 17.95 M |
VTv Therapeutics Investor Information
About 39.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 4.37. vTv Therapeutics had not issued any dividends in recent years. The entity had 1:40 split on the 21st of November 2023. Based on the key indicators related to VTv Therapeutics' liquidity, profitability, solvency, and operating efficiency, vTv Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.VTv Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. VTv Therapeutics has an asset utilization ratio of 0.0817 percent. This implies that the Company is making $8.17E-4 for each dollar of assets. An increasing asset utilization means that vTv Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.VTv Therapeutics Ownership Allocation
The market capitalization of VTv Therapeutics is $40.28 Million. vTv Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.VTv Therapeutics Profitability Analysis
The company reported the previous year's revenue of 9 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (9.93 M).About VTv Therapeutics Valuation
The stock valuation mechanism determines VTv Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of vTv Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of VTv Therapeutics. We calculate exposure to VTv Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of VTv Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -13.6 M | -14.3 M | |
| Pretax Profit Margin | (11.09) | (11.65) | |
| Operating Profit Margin | (10.05) | (10.56) | |
| Net Loss | (11.18) | (11.74) | |
| Gross Profit Margin | 0.86 | 0.90 |
VTv Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as VTv Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.1 M |
VTv Therapeutics Current Valuation Indicators
VTv Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final VTv Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as VTv Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use VTv Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes VTv Therapeutics' worth.Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.